Freeline Therapeutics Holdings is a clinical-stage, systemic adeno-associated virus-based gene therapy company. Co.'s pipeline includes programs in the clinic and late-stage preclinical product candidates, as well as research programs targeting applications for systemic gene therapy. Co.'s product candidate, verbrinacogene setparvovec (FLT180a) is intended for the treatment of patients in whom a deficiency of functional clotting Factor IX, causes moderate or severe hemophilia B. Co. is also developing FLT190 for the treatment of Fabry disease, as well as FLT201 and FLT210, for the treatment of Gaucher disease and hemophilia A, respectively. The FRLN stock yearly return is shown above.
The yearly return on the FRLN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FRLN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|